Insulet Corporation insider trading
Every open-market purchase and sale by Insulet Corporation's officers, directors and largest shareholders since November 4, 2021, and what the share price did next.
| Date | Insider | Trade | Shares | Price | Value | 1M after | 3M after | 6M after |
|---|
Does following Insulet Corporation’s insiders pay?
From March 3, 2010 to August 24, 2026, 37 insiders reported 28 open-market purchases and 66 sales not made under a pre-set plan in Insulet Corporation. Twelve months after each purchase was reported, the shares were +30.6% against the S&P 500 on average (median +23.3%), over 22 purchases with a full year of prices; 82% beat the index. After sales, the shares moved +4.7% against the index over 12 months (a negative figure means selling was the right call). Buying each purchase the day after it was reported, an equal amount each, held 12 months or until that insider reported a sale, would have turned $10,000 on March 12, 2015 into $16,469 by November 2, 2026, +4.4% a year. It held shares 59% of the time; the S&P 500 on those same days, with Treasury bills otherwise, made $27,367 (+9.1% a year), and held throughout $44,331 (+13.7%).
| Insider | Role | Purchases | 12 months after their purchases | Beat the S&P 500 | Sales | 12 months after their sales | Latest report |
|---|---|---|---|---|---|---|---|
| Alpuche Charles | Advisor | 2 | +64.5% (2) | 100% | 9 | −14.1% (9) | March 14, 2023 |
| Thomas Bradley A | EVP Human Resources | 6 | +42.4% (6) | 100% | 2 | +9.9% (2) | March 20, 2018 |
| Borio Luciana | Director | 0 | — | — | 6 | −16.5% (5) | June 4, 2026 |
| Sullivan Patrick J | CEO and Chairman of the Board | 5 | +19.9% (5) | 80% | 0 | — | December 5, 2016 |
| Christensen Bret | EVP and CCO | 0 | — | — | 4 | −21.3% (4) | November 21, 2022 |
| Field Mark N | SVP & Chief Technology Officer | 0 | — | — | 4 | +42.1% (4) | September 10, 2024 |
| Hopfield Jessica | Director | 2 | +56.6% (2) | 100% | 2 | −30.1% (2) | May 14, 2025 |
| Scannell Timothy J | Director | 1 | −3.7% (1) | 0% | 3 | +44.3% (3) | September 11, 2024 |
| Fallon John A. | Director | 0 | — | — | 3 | +9.8% (3) | May 25, 2021 |
| Lemoine David A | Director | 0 | — | — | 3 | +25.4% (3) | November 12, 2021 |
| Sommer Regina O | Director | 0 | — | — | 3 | +27.0% (3) | March 14, 2017 |
| Abdel-Malek Aiman | EVP & Chief Technology Officer | 0 | — | — | 2 | +69.4% (2) | March 14, 2019 |
| Budden Lauren | Group VP, CAO and Controller | 0 | — | — | 2 | +10.7% (2) | December 11, 2024 |
| Crawford Sally | Director | 0 | — | — | 2 | −18.4% (2) | June 7, 2021 |
| Depietro Ruthann | Vice President of Quality | 0 | — | — | 2 | +9.1% (2) | April 5, 2010 |
| Diehl R Anthony | Secretary and General Counsel | 0 | — | — | 2 | +9.1% (2) | April 5, 2010 |
| Jaffe Ross A Md | Director | 0 | — | — | 2 | −4.2% (2) | February 22, 2012 |
| Levangie Daniel J | President, Drug Delivery | 0 | — | — | 2 | +24.0% (2) | March 11, 2016 |
| Mcevoy Ashley | President and CEO | 2 | — | — | 0 | — | August 24, 2026 |
| Minogue Michael R | Director | 2 | −65.4% (1) | 0% | 0 | — | February 26, 2026 |
| Petrovic Shacey | Director | 0 | — | — | 2 | +31.4% (2) | February 29, 2024 |
| Singh Prem | SVP, Global Operations | 0 | — | — | 2 | −17.1% (2) | September 9, 2025 |
| Stonesifer Timothy C. | Director | 2 | — | — | 0 | — | June 4, 2026 |
| Zakrzewski Joseph S | Director | 0 | — | — | 2 | +29.2% (2) | March 3, 2017 |
| Benjamin Eric | EVP, CPXPO | 0 | — | — | 1 | −4.9% (1) | December 17, 2024 |
| Chadwick Ana Maria | EVP, CFO & Treasurer | 1 | +54.3% (1) | 100% | 0 | — | August 29, 2024 |
| Colleran David | SVP, Secretary and GC | 0 | — | — | 1 | +85.2% (1) | March 5, 2019 |
| Cousin Laetitia | SVP, Reg, Quality & Compliance | 0 | — | — | 1 | −79.4% (1) | September 9, 2025 |
| Frederick Wayne A.I. | Director | 0 | — | — | 1 | — | December 16, 2025 |
| Hollingshead James | President and CEO | 1 | −26.2% (1) | 0% | 0 | — | August 29, 2023 |
| Kapples John W. | SVP and General Counsel | 0 | — | — | 1 | −77.3% (1) | May 15, 2025 |
| Manea Dan | SVP, Chief HR Officer | 0 | — | — | 1 | −50.8% (1) | November 21, 2022 |
| Mullen James C | Director | 1 | +12.0% (1) | 100% | 0 | — | November 14, 2017 |
| Nevinny Corinne H | Director | 0 | — | — | 1 | −11.3% (1) | May 14, 2021 |
| Ryan William Patrick | Chief Operating Officer | 1 | +10.9% (1) | 100% | 0 | — | May 6, 2015 |
| Spears Michael P | SVP, QA and RA | 1 | +94.8% (1) | 100% | 0 | — | May 18, 2017 |
| Weatherman Elizabeth H | Director | 1 | — | — | 0 | — | June 3, 2026 |
When several insiders traded Insulet Corporation
Months when 2 or more insiders became net buyers, or 3 or more net sellers, of Insulet Corporation in reports dated in the 91 days before the month end, and how the stock did against the S&P 500 from that month end. After the 6 buying crowds with six months of prices, it averaged +16.5% against the index. After 6 selling crowds, +13.0%. One company's history is too short to judge by; the test across every company is the better guide.
| Month | Crowd | 3 months on, vs S&P 500 | 6 months | 12 months |
|---|---|---|---|---|
| June 30, 2026 | 2 buying | −15.3% | not yet | not yet |
| February 27, 2026 | 3 buying | −51.8% | −53.9% | not yet |
| June 30, 2025 | 3 selling | −8.8% | −20.5% | −71.2% |
| June 28, 2024 | 3 selling | +9.7% | +21.3% | +34.0% |
| June 30, 2021 | 4 selling | −0.2% | −13.9% | −10.0% |
| March 29, 2019 | 3 selling | +21.3% | +66.8% | +89.1% |
| March 29, 2018 | 3 selling | −1.9% | +10.2% | −0.6% |
| November 30, 2017 | 2 buying | +2.5% | +27.6% | +11.1% |
| May 31, 2017 | 3 buying | +35.4% | +60.1% | +109.1% |
| December 30, 2016 | 3 buying | +8.1% | +26.4% | +60.5% |
| May 31, 2016 | 3 buying | +37.4% | +11.1% | +22.4% |
| May 29, 2015 | 4 buying | +9.0% | +27.9% | +5.2% |